FDA Has Taken Cautious Approach With Mifepristone, Review Suggests

FDA Has Taken Cautious Approach With Mifepristone, Review Suggests

(MedPage Today) -- The FDA has taken a cautious and scientific evidence-based approach to regulating mifepristone (Mifeprex) over the years, contrary to what the Trump administration has alleged, an analysis of agency documents found. In a qualitative...

Federal and state abortion pill cases set for key developments in 2026

(The Lion)–A series of high-stakes federal lawsuits challenging the FDA’s regulation of mifepristone – and others contesting state restrictions on the drug – will keep chemical abortion at the center of national legal fights throughout 2026. Six Republican states – Florida, Idaho, Kansas, Louisiana, Missouri and Texas – are involved in three lawsuits that challenge under-regulated access to mifepristone, the first of two chemical abortion pills.…

Abortion Pill: Examining the Political Debate

The abortion pill mifepristone is one of the most politically contentious medications in the United States, one increasingly targeted by anti-abortion activists trying to limit its availability and championed by abortion rights supporters seeking greater access. Both sides have pressured the Food and Drug Administration for years — and both have, at times, accused the FDA of political considerations in its regulatory decisions about the medicati…